Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Nederlands Tijdschrift Voor Tandheelkunde
|
April 1, 1992
[Prostate cancer]
P Fernandez del Moral, W P Witjes
Progress in Clinical and Biological Research
|
January 1, 1988
LHRH-analogues therapy for metastatic prostate cancer
F M Debruyne, P Fernandez del Moral, A D Geboers
Urology
|
May 1, 1989
Ketoconazole high dose in management of hormonally pretreated patients with progressive metastatic prostate cancer. Dutch South-Eastern Urological Cooperative Group
F J Witjes, F M Debruyne, P Fernandez del Moral, et al.
European Urology
|
January 1, 1995
Improved subjective responses to orchiectomy plus nilutamide (anandron) in comparison to orchiectomy plus placebo in metastatic prostate cancer. International Anandron Study Group
G A Dijkman, P Fernandez del Moral, F M Debruyne, et al.
Urology
|
August 1, 1988
Can combined DES and LHRH depot therapy (ICI 118630) prevent endocrinologic and clinical flare-up in metastatic prostate cancer?
P Fernandez del Moral, T T Litjens, E H Weil, et al.
Urology
|
December 1, 1996
Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group
P Fernandez del Moral, G A Dijkman, F M Debruyne, et al.
Cancer
|
June 15, 1990
Analysis of prognostic factors in disseminated prostatic cancer. An update. Dutch Southeastern Urological Cooperative Group
P F Mulders, G A Dijkman, P Fernandez del Moral, et al.
The Prostate
|
September 19, 1997
Liarozole (R75251) in hormone-resistant prostate cancer patients
G A Dijkman, P Fernandez del Moral, J Bruynseels, et al.
Nederlands Tijdschrift Voor Geneeskunde
|
April 26, 1986
[Treatment of advanced prostate carcinoma with a depot form of an LH-RH analog: preliminary endocrinological and clinical results]
T T Litjens, P Fernandez del Moral, J P van Laarhoven, et al.
European Urology
|
January 1, 1992
Value of biochemical markers in the management of disseminated prostatic cancer
P F Mulders, P Fernandez del Moral, A G Theeuwes, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Nederlands Tijdschrift Voor Tandheelkunde
|
April 1, 1992
[Prostate cancer]
P Fernandez del Moral, W P Witjes
Progress in Clinical and Biological Research
|
January 1, 1988
LHRH-analogues therapy for metastatic prostate cancer
F M Debruyne, P Fernandez del Moral, A D Geboers
Urology
|
May 1, 1989
Ketoconazole high dose in management of hormonally pretreated patients with progressive metastatic prostate cancer. Dutch South-Eastern Urological Cooperative Group
F J Witjes, F M Debruyne, P Fernandez del Moral, et al.
European Urology
|
January 1, 1995
Improved subjective responses to orchiectomy plus nilutamide (anandron) in comparison to orchiectomy plus placebo in metastatic prostate cancer. International Anandron Study Group
G A Dijkman, P Fernandez del Moral, F M Debruyne, et al.
Urology
|
August 1, 1988
Can combined DES and LHRH depot therapy (ICI 118630) prevent endocrinologic and clinical flare-up in metastatic prostate cancer?
P Fernandez del Moral, T T Litjens, E H Weil, et al.
Urology
|
December 1, 1996
Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group
P Fernandez del Moral, G A Dijkman, F M Debruyne, et al.
Cancer
|
June 15, 1990
Analysis of prognostic factors in disseminated prostatic cancer. An update. Dutch Southeastern Urological Cooperative Group
P F Mulders, G A Dijkman, P Fernandez del Moral, et al.
The Prostate
|
September 19, 1997
Liarozole (R75251) in hormone-resistant prostate cancer patients
G A Dijkman, P Fernandez del Moral, J Bruynseels, et al.
Nederlands Tijdschrift Voor Geneeskunde
|
April 26, 1986
[Treatment of advanced prostate carcinoma with a depot form of an LH-RH analog: preliminary endocrinological and clinical results]
T T Litjens, P Fernandez del Moral, J P van Laarhoven, et al.
European Urology
|
January 1, 1992
Value of biochemical markers in the management of disseminated prostatic cancer
P F Mulders, P Fernandez del Moral, A G Theeuwes, et al.
Page
of 2